Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Wheaton Precious Metals Corp — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Wheaton Precious Metals Corp trades at $130.54 (market cap $61.55B). The key difference: Wheaton Precious Metals Corp is far larger — about 21.5× Dyne Therapeutics Inc. Common Stock's market cap, and Wheaton Precious Metals Corp pays a 0.57% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Wheaton Precious Metals Corp for 66 Days on average.
| DYN | WPM | |
|---|---|---|
Market Cap | $2.86B | $61.55B |
Volume | 3,341,579 | 932,802 |
Sector | Health | Basic Materials |
52-Week High | $26.78 | $165.72 |
52-Week Low | $14.60 | $94.37 |
Typical Hold Time | 0 Days | 66 Days |
Enterprise Value | $2.18B | $63.43B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Wheaton Precious Metals (WPM) trades at $129.58, down 6.18% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported record 2025 revenue of $2.31 billion and net income of $1.47 billion, with earnings beating estimates in recent quarters. Management targets 50% production growth by 2030 without new capital, supported by a strong deal pipeline.
WPM presents a growth opportunity with high profitability margins and analyst consensus favoring a buy rating, but faces risks from gold price volatility and execution of expansion plans. The stock's valuation multiples are elevated, requiring sustained earnings growth to justify current levels amid macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
